US2023225981A1PendingUtilityA1

Low dose topiramate/phentermine composition and methods of use thereof

Assignee: VIVUS LLCPriority: Jun 9, 2008Filed: Mar 22, 2023Published: Jul 20, 2023
Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority
A61K 9/5015A61K 31/35A61K 31/357A61K 31/137A61K 9/28A61K 31/7048A61K 9/4808A61K 9/5026A61K 9/5047A61P 11/00A61P 11/06A61P 25/00A61P 25/06A61P 3/00A61P 3/04A61P 3/06A61P 9/12A61P 3/10
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

Claims

exact text as granted — not AI-modified
1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:
 an effective amount of topiramate and phentermine.   
     
     
         2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.

Join the waitlist — get patent alerts

Track US2023225981A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.